Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients with Stage III Soft Tissue Sarcomas of the Extremity By Ogkologos - December 2, 2024 845 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SU2C-SARC032 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR ‘Normal’ cells and ‘cancer’s surprising circular DNA’: Inside Cancer Grand Challenges... June 23, 2022 How Genomic Testing Brought Me a Sense of Control During Metastatic... April 6, 2021 EMA Recommends Extending Indications for Lisocabtagene Maraleucel November 12, 2025 EMA Recommends Granting a Marketing Authorisation for Quizartinib October 2, 2023 Load more HOT NEWS Oligoprogression in Metastatic NSCLC Could Be Effectively Treated with SBRT Plus... Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation Combination Chemo Helps People with Leiomyosarcoma Live Longer Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial
